- Home
- STTK vs SOND Comparison
STTK vs SOND Comparison
Compare STTK & SOND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SOND
- Stock Information
- Founded
- STTK 2016
- SOND 2014
- Country
- STTK United States
- SOND United States
- Employees
- STTK N/A
- SOND N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SOND Hotels/Resorts
- Sector
- STTK Health Care
- SOND Consumer Discretionary
- Exchange
- STTK Nasdaq
- SOND Nasdaq
- Market Cap
- STTK 54.4M
- SOND 50.7M
- IPO Year
- STTK 2020
- SOND N/A
- Fundamental
- Price
- STTK $1.16
- SOND $3.17
- Analyst Decision
- STTK Hold
- SOND Hold
- Analyst Count
- STTK 3
- SOND 1
- Target Price
- STTK $2.00
- SOND $4.00
- AVG Volume (30 Days)
- STTK 329.4K
- SOND 53.8K
- Earning Date
- STTK 11-14-2024
- SOND 12-31-2024
- Dividend Yield
- STTK N/A
- SOND N/A
- EPS Growth
- STTK N/A
- SOND N/A
- EPS
- STTK N/A
- SOND N/A
- Revenue
- STTK $6,435,000.00
- SOND $623,240,000.00
- Revenue This Year
- STTK $313.04
- SOND $28.50
- Revenue Next Year
- STTK N/A
- SOND $17.62
- P/E Ratio
- STTK N/A
- SOND N/A
- Revenue Growth
- STTK 382.75
- SOND 15.39
- 52 Week Low
- STTK $0.94
- SOND $0.88
- 52 Week High
- STTK $11.76
- SOND $10.50
- Technical
- Relative Strength Index (RSI)
- STTK 44.02
- SOND 44.44
- Support Level
- STTK $1.07
- SOND $3.22
- Resistance Level
- STTK $1.38
- SOND $3.52
- Average True Range (ATR)
- STTK 0.12
- SOND 0.28
- MACD
- STTK 0.01
- SOND -0.04
- Stochastic Oscillator
- STTK 27.88
- SOND 17.76
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About SOND Sonder Holdings Inc.
Sonder Holdings Inc is engaged in providing short and long-term accommodations to travelers in various cities across North America, Europe, and the Middle East. The Sonder units in each apartment-style building and each hotel property are selected, designed, and managed directly by the Company. The Company generates revenues by providing short-term or month-to-month accommodations to its guests. The Company also provides accommodations to travelers through boutique hotels.